04th week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100021431 | Agent for Promoting the Production of Thioredoxin - A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety. | 2010-01-28 |
20100021432 | Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus - The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus. | 2010-01-28 |
20100021433 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 2010-01-28 |
20100021434 | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases - Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided. | 2010-01-28 |
20100021435 | PANCREATIC ISLET-LIKE CELLS - The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MD-SCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided. | 2010-01-28 |
20100021436 | MULTIPOTENT ADULT STEM CELL DERIVED FROM CANINE UMBILICAL CORD BLOOD, PLACENTA AND CANINE FETUS HEART, METHOD FOR PREPARING THE SAME AND CELLULAR THERAPEUTICS CONTAINING THE SAME - The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention are derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart. The adult stem cells have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases due to the ability to differentiate into osteogenic cells and neural cells. | 2010-01-28 |
20100021437 | NEURAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS - The present invention provides novel populations of neural stem cells derived from induced pluripotent stem cells, and methods for making and using the same. | 2010-01-28 |
20100021438 | KIDNEY DERIVED STEM CELLS AND METHODS FOR THEIR ISOLATION, DIFFERENTIATION AND USE - The invention relates generally to methods for isolation and culture of kidney stem cells, cells isolated by the methods, and therapeutic uses for those cells. | 2010-01-28 |
20100021439 | METHODS AND COMPOSITIONS FOR TREATING INTERVERTEBRAL DISC DEGENERATION - A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived. | 2010-01-28 |
20100021440 | USE OF TROPOELASTIN FOR REPAIR OR RESTORATION OF TISSUE - The present invention relates to tropoelastin and to tissue repair and restoration using elastic materials. Disclosed is a process for producing an elastic material from tropoelastin including heating a solution of tropoelastin having an alkaline pH to form an elastic material from the tropoelastin in the solution. Also disclosed are elastic materials prepared according to this process and their applications. | 2010-01-28 |
20100021441 | MHC MOLECULE-BINDING TUMOR-ASSOCIATED PEPTIDES - The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the pepti | 2010-01-28 |
20100021442 | METHOD FOR PROMOTING IMMUNOTHERAPY USING AN AGENT FOR ELEVATING DENDRITIC CELL PRECURSOR LEVEL IN BLOOD - Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a key point in performing a therapy with the use of dendritic cells in practice to elevate dendritic cell precursor level in the peripheral blood of a patient. The present invention provides an agent for elevating dendritic cell precursor level in the blood which comprises an agonist to a receptor expressed in immature dendritic cells or a functional derivative thereof as the active ingredient. | 2010-01-28 |
20100021443 | METHOD OF PREPARING LUNG ALVEOLAR EPITHELIAL TYPE II CELLS DERIVED FROM EMBRYONIC STEM CELLS - A method of preparing a population of in vitro cultured cells of alveolar epithelial type II (ATII) cell lineage derived from at least one embryonic stem cell is disclosed which comprises (a) culturing said at least one embryonic stem cell in vitro in a medium comprising Matrigel®, to produce differentiated cells without formation of an embryonic body, wherein at least some of the differentiated cells are of ATII cell phenotype; (b) identifying the differentiated cells of ATII cell phenotype by detecting expression of at least one biomarker of ATII cells; (c) isolating the differentiated cells having ATII cell phenotype; and (d) cloning the isolated cells to produce a population of cells having ATII cell phenotype. The resulting cells are preferably >99% pure ATII phenotype lineage and are potentially useful therapeutically for treating lung injury and disease. | 2010-01-28 |
20100021444 | BLOOD-ADIPONECTIN-CONCENTRATION INCREASE-ACCELERATOR AND/OR DECREASE-INHIBITOR THEREOF AND VISCERAL FAT ACCUMULATION INHIBITOR - Disclosed is an agent for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, or a food, beverage or animal feed for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, which comprises a culture or cell of a lactic acid bacterium belonging to the genus | 2010-01-28 |
20100021445 | AGENT FOR REDUCING VISCERAL FAT - Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the | 2010-01-28 |
20100021446 | Use of Polypeptides Against Diseases Caused by Protozoans - The present invention relates to the use of isolated polypeptides as coccidiostat and/or histomonastat. An example of a polypeptide of the invention is the so-called L12 protein from | 2010-01-28 |
20100021447 | Medicament for Treating Problems Relating to Fertility and Pregnancy, and Autoimmune Diseases, and for Inducing an Immunological Tolerance in Transplant Patients, and Method for Producing Said Medicament - A medicament for treating pregnancy disorders or for inducing an immunological tolerance in patients with autoimmune diseases or transplantation processes, contains at least one each of a) a precursor hCG β subunit of the human choriongonadotropine (hCG) selected from hCG β6 according to SEQ ID NO 1 or SEQ ID NO 2 and hCG β7 according to SEQ ID NO 5 or a mature hCG β subunit selected from hCG β6 according to SEQ ID NO 3 or SEQ ID NO 4 and hCG β7 according to SEQ ID NO 6 or glycolised fragments of these sequences; and b) a precursor α subunit of hCG according to SEQ ID NO 9 or the mature α subunit of hCG according to SEQ ID NO 10 or glycolysed fragments of these sequences, wherein the β subunits and the α subunits are preferably used in equimolar quantities. | 2010-01-28 |
20100021448 | I-CREI MEGANUCLEASE VARIANTS WITH MODIFIED SPECIFICITY, METHOD OF PREPARATION AND USES THEREOF - Method of preparing 1-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors. | 2010-01-28 |
20100021449 | ANGIOGENIN COMPLEXES (ANGex) AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed. | 2010-01-28 |
20100021450 | Lys K Endolysin Is Synergistic with Lysostaphin Against MRSA - Multi-drug resistant superbugs are a persistent problem in modern health care. LysK is a staphylococcal bacteriophage endolysin from the phage K. It is a peptidoglycan hydrolase enzyme that can lyse many staphylococcal strains and thus is a potent antimicrobial against | 2010-01-28 |
20100021451 | Uses and compositions for treatment of ankylosing spondylitis - The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject. | 2010-01-28 |
20100021452 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas. | 2010-01-28 |
20100021453 | TARGETING OF TRIACYLCLYCEROL SYNTHASE GENE FOR TUBERCULOSIS TREATMENT - Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection. | 2010-01-28 |
20100021454 | Antibodies With Immune Effector Activity And That Internalize In Endosialin-Positive Cells - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments. | 2010-01-28 |
20100021455 | METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine. | 2010-01-28 |
20100021456 | DRUG FOR INHIBITING,PREVENTING OR TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to the use of at least one interleukin-17F inhibitor and/or of at least one IL-17 receptor inhibitor, for the manufacture of a medicament for inhibiting, preventing or treating rheumatoid arthritis. | 2010-01-28 |
20100021457 | DETECTION SYSTEM AND USES THEREFOR - A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group; iv) a modulator; and v) a detector; wherein proximity of the first and second reporter components generates a signal capable of detection by the detector; and wherein the modulator modulates the association of the second interacting group with the third interacting group; such that monitoring the signal generated by proximity of the first and second reporter components by the detector constitutes monitoring the association of the first and third agents. | 2010-01-28 |
20100021458 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - The present invention relates to polycyclic antiviral compounds, and salts thereof, methods for their preparation and compositions containing them, and the use of the compounds and composition in the treatment of viral infections. | 2010-01-28 |
20100021459 | POLYPEPTIDE CONSTRUCTS FOR INTRACELLULAR DELIVERY - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 2010-01-28 |
20100021460 | Methods of Treating Autoimmune Diseases Using CD4 Antibodies - Methods of treating autoimmune disorders in mammalian subjects using non-depleting CD4 antibodies, alone or in combination with other compounds, are provided. | 2010-01-28 |
20100021461 | IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF - A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight. | 2010-01-28 |
20100021462 | GASP1: A FOLLISTATIN DOMAIN CONTAINING PROTEIN - The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration. | 2010-01-28 |
20100021463 | Antibodies to ip-10 for treating bone diseases with bone destruction - The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating a disease or disorder associated with the expression of RANKL (receptor activator of NF-κB ligand), (ii) a method for inhibiting the expression of RANKL and (iii) a method for screening an antibody drug candidate to inhibit the expression of RANKL. | 2010-01-28 |
20100021464 | METHODS OF WOUND CARE AND TREATMENT - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2010-01-28 |
20100021465 | BORIS ISOFORMS AND METHODS OF DETECTING AND TREATING DISEASE - A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same. | 2010-01-28 |
20100021466 | Antagonistic Human LIGHT-Specific Human Monoclonal Antibodies - Provided herein are antibodies, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide. In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental. | 2010-01-28 |
20100021467 | METHOD OF DETECTING A CANCER CELL BY ABERRANT EXPRESSION OF A HUMAN K+ ION CHANNEL - The present invention relates to a novel human K | 2010-01-28 |
20100021468 | NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANITGEN, NY ESO-1 - The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4 | 2010-01-28 |
20100021469 | FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY - The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM. | 2010-01-28 |
20100021470 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 2010-01-28 |
20100021471 | CARBON NANOTUBE-BASED DRUG DELIVERY SYSTEMS AND METHODS OF MAKING SAME - The present invention includes a conjugates comprising a carbon nanotube with at least one covalently attached recognition module, and at least one covalently attached pharmaceutical compound or a precursor of the pharmaceutical compound, | 2010-01-28 |
20100021472 | METHODS FOR DIAGNOSING AND TREATING CANCER - Aspects of the present invention relate to molecular biology and medicine. More specifically, some embodiments include methods for treating and/or diagnosing inflammation and/or cancer using agents that inhibit the binding of a pro-inflammatory protein or protein complex (e.g., S100A8 and/or S100A9) to a carboxylated glycan expressed on a myeloid (e.g., MDSC), monocytic, dendritic, endothelial, or tumor cell. | 2010-01-28 |
20100021473 | Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor - Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the ligands described further comprise a toxin. In other embodiments, the ligands further comprise half-life extending moieties. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 2010-01-28 |
20100021474 | METHODS AND COMPOSITIONS FOR TARGETING HEPSIN - Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided. | 2010-01-28 |
20100021475 | METHODS AND COMPOSITIONS FOR INHIBITING THE GROWTH OF HEMATOPOIETIC MALIGNANT CELLS - Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy. | 2010-01-28 |
20100021476 | High Affinity Human Antibodies to Human IL-4 Receptor - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 2010-01-28 |
20100021477 | DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES - Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies. | 2010-01-28 |
20100021478 | DIAGNOSTIC ANTIBODY ASSAY - The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 2010-01-28 |
20100021479 | Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues - The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided. | 2010-01-28 |
20100021480 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME - This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is ex vivo conjugated with a specific functional group on a blood protein through a reactive group, the low-molecular-weight bioactive substance is available as a drug for treatment and prevention in mammals including human and selected from the group consisting of a natural substance; and a method of a stable and efficient in vivo delivery of the low-molecular-weight bioactive substance based on the use of the bioactive substance-blood protein conjugate. | 2010-01-28 |
20100021481 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY - Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient. | 2010-01-28 |
20100021482 | NOVEL DEATH ASSOCIATED PROTEINS, AND THAP1 AND PAR4 PATHWAYS IN APOPTOSIS CONTROL - The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies. | 2010-01-28 |
20100021483 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 2010-01-28 |
20100021484 | Compositions, Methods and Kits Relating to Poxvirus Subunit Vaccines - The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them. | 2010-01-28 |
20100021485 | COMBINATION THERAPY METHOD AND FORMULATION - This invention concerns a pharmaceutical formulation and method for treating autoimmune disorders. The formulation and method provide for a combination therapy regimen wherein two separate substances are administered to a patient having or predisposed to having the disorder. The two components comprise at least one immunomodulatory peptide and a chloroquine derivative. The combination of the two components can be administered together or separately. | 2010-01-28 |
20100021486 | TSLP VACCINE FOR THE TREATMENT OF TH2 MEDIATED INFLAMMATORY CONDITIONS - The invention relates to compositions for the treatment of TH2 mediated inflammatory conditions. The compositions are vaccines comprising a non-primate TSLP or fragments thereof to be used as a vaccine to treat humans with excessive mediated inflammatory conditions. For the treatment of TH2 mediate inflammatory conditions in other non-human mammals the TSLP of the species to be vaccinated is being used as antigen. | 2010-01-28 |
20100021487 | VACCINES AND METHODS FOR CONTROLLING ADIPOSITY - The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety. | 2010-01-28 |
20100021488 | HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS - A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions. | 2010-01-28 |
20100021489 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection - Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection. | 2010-01-28 |
20100021490 | Preparation of soluble N-protein/truncated P-protein complexes or N-proteinssoluble in a virus of the paramyxoviridae family and use thereof in vaccines - The invention relates to a method for preparation of soluble N-protein/truncated P-protein complex of a virus of the family Paramyxoviridae, complexes prepared thus and the soluble N-proteins which may be isolated from said complexes. The invention further relates to vaccine compositions comprising said N-protein/truncated P-protein complexes or N-proteins from Paramyxoviridae. | 2010-01-28 |
20100021491 | PROTEIN KINASE DEFICIENT, IMMUNOLOGICALLY ACTIVE CMVpp65 MUTANT CELLULAR VACCINES - This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAs, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments related to the invention are methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors. | 2010-01-28 |
20100021492 | MORAXELLA CATARRHALIS OUTER MEMBRANE PROTEIN-106 POLYPEPTIDE, GENE SEQUENCE AND USES THEREOF - The invention discloses the | 2010-01-28 |
20100021493 | EXTRACTS OF APHANIZOMENON FLOS AQUAE AND NUTRITIONAL, COSMETIC AND PHARMACEUTICAL COMPOSITONS CONTAINING THE SAME - The invention provides extracts of the microalga | 2010-01-28 |
20100021494 | HEPATITIS-RELATED PREVENTIVE OR THERAPEUTIC AGENTS - The present disclosure relates to provide a novel hepatitis-related therapeutic or preventive agent. The present disclosure provides a hepatitis-related preventive or therapeutic agent including a phlorotannin. | 2010-01-28 |
20100021495 | DIET PRODUCT COMPRISING ALGINATE - The present invention relates to a diet product comprising an alginate in an aqueous dissolved or swelled form at a pH value causing the alginate not to gel. | 2010-01-28 |
20100021496 | METHODS, KITS, AND ANTIBODIES FOR QUANTITATIVE DETERMINATION OF PARATHYROID HORMONE MOLECULES WITH INTACT C-TERMINUS - The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and C-terminal parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as chronic renal failure, hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of C-terminal parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of C-terminal parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values, one is able to differentiate chronic renal failure, parathyroid and bone related disease states, as well as differentiate such states from normal states. | 2010-01-28 |
20100021497 | IPV-DPT VACCINE - The invention provides a process for producing a combined vaccine containing an inactivated Sabin strain of poliovirus, a | 2010-01-28 |
20100021498 | LIVE, ATTENUATED PNEUMOCOCCAL VACCINE - This invention relates to a live mutated strain of | 2010-01-28 |
20100021499 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES - The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines. | 2010-01-28 |
20100021500 | Processes for treating subjects carrying viral infectious agent - This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention. | 2010-01-28 |
20100021501 | LIVE VACCINE STRAINS OF FRANCISELLA - A strain of | 2010-01-28 |
20100021502 | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT - This invention relates to novel compositions of botulinum toxin that are stabilized using HTV-TAT fragments or derivatives of HTV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments. | 2010-01-28 |
20100021503 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from | 2010-01-28 |
20100021504 | TREATMENT AND PREVENTION OF ALLERGIC AIRWAYS DISEASES - The present invention provides a method for the treatment or prevention of an allergic airways disease in a subject, the method comprising administering to the subject a composition comprising | 2010-01-28 |
20100021505 | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients - Method of preventing or reducing diarrhea and/or steatorrhea in HIV-positive patients being treated with High Activity Antiretroviral drugs containing protease inhibitors, nucleoside reverse transcriptase inhibitors or non-nucleoside reverse transcriptase inhibitors. The method includes the steps of: administering to the HIV-positive patient a High Activity Antiretroviral drug containing a protease inhibitor, a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor; and co-administering with the HAART drug a gastric acid-resistant polymer-coated and buffered digestive enzyme composition containing pancreatic proteases, lipases, co-lipases, nucleases, amylases and other bio-active substances produced by the pancreatic gland. | 2010-01-28 |
20100021506 | NITRIC OXIDE GEL APPARATUS AND METHOD - Gel strips containing reactants capable of reacting to form nitric oxide are maintained separate until application. Upon application, the gel strips are placed in contact with one another, and may mix, or operate by diffusion, to deliver nitric oxide directly to the stream of breathing air of a user. Adhesive strips bonded to a substrate supporting the gel strips may provide for securing the nitric oxide generator directly to an upper lip of a user for breathing the nitric oxide through the nostrils. | 2010-01-28 |
20100021507 | Method and Composition for Making an Orally Disintegrating Dosage Form - The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms. | 2010-01-28 |
20100021508 | METHOD FOR TREATING HYPERSENSITIVE TEETH - A method for imparting a teeth-desensitising effect to a food, cosmetic or pharmaceutical which comprises combining said food, cosmetic or pharmaceutical with a teeth-desensitising effective amount of a polyol. | 2010-01-28 |
20100021509 | Cosmetics containing a multi-functional composite powder - This invention provides cosmetics containing a multi-functional composite powder having the properties of (a) an excellent adhesiveness, (b) an excellent extendability, (c) an appropriate glossy effect, (d) a homogeneous cosmetic film, (e) an appropriate covering capability, (f) a cosmetic film not causing a white masking, (g) a high compatibility between a color appearance of cosmetics and a color tone of the cosmetic film, (h) an excellent soft-focusing capability, (i) an excellent ultraviolet protective effect, and the like. The multi-functional composite powder is constituted by a scale-like base material, a group of particles comprising at least fine particles of titanium dioxide deposited on a surface of the scale-like base material, and a thin film of a composite oxide containing titanium and iron coated thereon. | 2010-01-28 |
20100021510 | NEURONAL EXOCYTOSIS INHIBITING PEPTIDES - The invention relates to peptides of general formula (I): | 2010-01-28 |
20100021511 | DISPERSION COMPOSITION, COSMETIC PREPARATION FOR SKIN CARE, AND METHOD FOR PRODUCING DISPERSION COMPOSITION - The present invention provides: a dispersion composition including a carotenoid-containing oily component, the dispersion composition being obtained by mixing an aqueous dispersion containing emulsion particles containing the carotenoid-containing oily component and a phospholipid or a derivative thereof with an aqueous composition containing ascorbic acid or a derivative thereof and an oily component that is 20% by mass or less relative to the mass of the whole dispersion composition, and the dispersion composition having emulsion particles having an average particle diameter of 200 nm or less; a dispersion composition including a carotenoid-containing oily component, the dispersion composition being obtained by mixing an aqueous dispersion containing emulsion particles containing a carotenoid-containing oily component and a phospholipid or a derivative thereof with an aqueous composition containing ascorbic acid or a derivative thereof and a pH adjusting agent, and the dispersion composition having a pH value in the range of 5 to 7.5; and a cosmetic preparation for skin care including one or other of the dispersion compositions. | 2010-01-28 |
20100021512 | Incontinence garments with a silver lining infection stopper - Antibiotics used to cure Uterine Tract Infections have resulted in the growth of MRSA. and other antibiotic resistant bacteria. The CDC guidelines state “Disposable diapers cause 95% of all UTI'S”. The procedures used for “prevention” are ineffective because millions of bacteria in incontinence garments continue to double every 20 minutes. Silver ions in bandages are used to cure severly damaged skin, such as in burns. The best two in a large scale test achieved results in just 30 minutes. This Invention uses silver ions in linings next to the skin to stop the growth of over 250 kinds of infectious bacteria on it's surface and the body parts it touches. It achieves results in 30 minutes, equal to the most highly rated bandages . . . for every level of incontinence for both sexes. | 2010-01-28 |
20100021513 | ABSORBANT SUBSTANCE AND METHOD OF PREPARATION THEREOF - The invention relates to a cellular substance, the method of preparation and uses thereof, in particular as an absorbent substance, and in particular for the manufacture of sponges and other products for household use. The cellular substance of the invention comprises a mixture of fibers of a hydrophilic polymer, and at least one elastomer, and has a cellular structure formed by cells whose size is between 0.2 μm and 10 mm, at least 1% of the cells, by volume as compared to the total cell volume, having a size of between 0.2 μm and 10 μm. The invention has application, particularly, in the area of absorbent products. | 2010-01-28 |
20100021514 | INFECTION-RESISTANT POLYURETHANE FOAMS, METHOD FOR PRODUCING THE SAME AND USE THEREOF IN ANTISEPTIC WOUND DRESSINGS - The present invention describes microbicidal hydrophilic polyurethane foams endowed with polyhexamethylenebiguanide (PHMB) and/or its hydrochloride and also a superabsorbent, wound contact materials obtainable therefrom and processes for producing the therapeutically endowed polyurethane foams and the wound contact materials obtainable therefrom. | 2010-01-28 |
20100021515 | NOVEL COMPOSITIONS OF FUNGAL INOCULA, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF FOR IMPROVING THE GROWTH OF CULTURES - This invention relates to novel compositions of fungal inocula, method for the preparation thereof, and use thereof for improving the growth of cultures. | 2010-01-28 |
20100021516 | DRUG DEPOTS HAVING ONE OR MORE ANCHORING MEMBERS - A drug depot implantable at or near a target tissue site beneath the skin of a patient is provided, the drug depot comprising a therapeutically effective amount of a drug and at least one surface adapted to receive one or more anchoring members so as to limit movement of the drug depot at or near the target tissue site, wherein at least one region of the drug depot is capable of releasing the therapeutically effective amount of the drug over a period of at least one day. In some embodiments, the drug depot provided can include an effective amount of at least analgesic and at least one anti-inflammatory agent at or near a target site, and can reduce, prevent or treat inflammation and/or pain, particularly postoperative pain. | 2010-01-28 |
20100021517 | NON-WOVEN FIBER FABRIC - In order to provide a non-woven fiber fabric, in particular, in the form of a flat material or as part of a flat material which can be used as a biodegradable material in medicine, in particular, as an implant or carrier material for living cells (tissue engineering) but also a non-woven fiber fabric which can be used in food technology in a variety of applications, in particular, as a preliminary product for foods, a non-woven fiber fabric is provided containing fibers consisting of a gelatin material, wherein the thickness of the fibers is on average 1 to 500 μm and wherein the non-woven fiber fabric has a plurality of areas, at which two or more fibers merge into one another without any phase boundary. | 2010-01-28 |
20100021518 | FOAM CARRIER FOR BONE GRAFTING - An improved osteogenic composition is provided. The composition comprises a foam that contains polymer beads having one or more growth factors such as bone morphogenic protein. Through use of this composition, bone, collagen and/or other tissue growth may be facilitated. | 2010-01-28 |
20100021519 | Compositions and Methods for Treating or Preventing Diseases of Body Passageways - The present invention provides compositions and methods for treating or preventing diseases associated with vascular and non-vascular body passageways, the method comprising the step of delivering to a body passageway a therapeutic agent delivered locally through a polymer matrix from an implanted stent or other structure. | 2010-01-28 |
20100021520 | BIOMATERIAL IMPLANTS - A biomaterial implant includes a mineralized collagen fibril scaffold. The collagen fibrils are formed from type I collagen monomers and display native-D band periodicity. The implant has load bearing capabilities and can be resorbed when implanted in a mammal's body. | 2010-01-28 |
20100021521 | Prosthesis for joint cartilage repair and method of manufacture - A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking the animal material, removing antigens from the animal material, subjecting the animal material to an alkaline treatment, coupling into the animal material active substances which are capable of adhering growth factor and stem cell, and packing the animal material in a container that contains a sterilization solution. | 2010-01-28 |
20100021522 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 2010-01-28 |
20100021523 | Medical Devices Having Inorganic Barrier Coatings - Medical devices having a barrier layer comprising an inorganic material. The medical device has a reservoir containing a therapeutic agent and the barrier layer is disposed over the reservoir. In one aspect, the barrier layer has one permeability to the therapeutic agent at one portion of the medical device and a different permeability at another portion of the medical device. In another aspect, the dosage amount of the therapeutic agent in the reservoir at one portion of the medical device is different from the dosage amount of the therapeutic agent in the reservoir at another portion of the medical device. In another aspect, a bioresorbable layer is disposed over the barrier layer at one or more portions of the medical device, wherein the bioresorbable layer comprises a bioresorbable material. Also, methods of coating a medical device are disclosed, in which a barrier layer over a medical device is formed using a lithographic etching process where a plurality of particles serve as an etch mask. | 2010-01-28 |
20100021524 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-01-28 |
20100021525 | Method for Producing Sterol Formulations - The invention relates to a method for producing coated sterol powders. According to said method, a) micronized sterol and/or stanol particles are provided in a mixer, b) the micronized sterol and/or stanol particles are wetted with a proteinaceous aqueous solution/dispersion, c) the wetted particles are mixed well and then dried, and d) the dried mixture is optionally size-reduced in a mill. Owing to their good wettability, the sterol-containing formulations produced according to this method can be incorporated into food items without technical complications and have good organoleptic and sensory properties especially when used in drinks and dairy products. | 2010-01-28 |
20100021526 | PH MODULATED FILMS FOR DELIVERY OF ACTIVES - The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film. | 2010-01-28 |
20100021527 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF AND HEMOSTATIC FOAM SUBSTRATES - The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof. The present invention also relates to novel hemostatic foam substrates, a method of manufacturing the foam substrates, and a method of stimulating hemostasis in a mammal using such foam substrates. | 2010-01-28 |
20100021528 | CONFORMABLE STRUCTURED THERAPEUTIC DRESSING - A conformable structured therapeutic dressing ( | 2010-01-28 |
20100021529 | STEP-DOWN ESTROGEN REGIMEN FOR WOMEN RECEIVING ESTROGEN THERAPY - The present invention relates to methods for continuous treatment of diseases, conditions and/or symptoms associated with deficient endogenous levels of estrogen in a woman already receiving a therapeutically effective dose of an estrogen. More particularly, the present invention provides a safe and efficient step-down regimen for women already receiving estrogen therapy and which are potentially overdosed. | 2010-01-28 |
20100021530 | ENHANCED TRANS-KERATIN DRUG DELIVERY - The teachings provided herein are directed to a system and method for delivering an anti-infective agent through the nail of a subject having a nail infection. The system can comprise a drug delivery mechanism comprising an anti-infective agent and a heating element and a holding mechanism for releasably attaching the drug delivery mechanism to the digit having the infected nail. The drug delivery mechanism does not comprise a nail-infection-agent-containing member or sponge for receiving and delivering the anti-infective agent to the infected nail. In addition, the holding mechanism comprises a substantially open structure that covers the infected nail and does not enclose the digit. The system facilitates an enhanced trans-keratin drug delivery of the anti-infective agent through the infected nail in a dark, warm, and moist environment that prevents the growth of fungi in the infected nail. The teachings also include a heatable bandage for treating an infected nail. | 2010-01-28 |